Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein

Molecular and Cellular Biology

Volumn 12, Issue 6, 1992, Pages 2606-2615

  Cox, Adrienne D ^a   Hisaka, Mark M ^a   Buss, Janice E ^a   Der, Channing J ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIA;

CHIMERIC PROTEIN; ISOPRENOID; PROTEIN;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; GROWTH INHIBITION; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROCESSING; RAT;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMAL; CELL DIVISION; CELL MEMBRANE; CELL TRANSFORMATION, NEOPLASTIC; CYSTEINE; DITERPENES; FARNESOL; GTP-BINDING PROTEINS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEIN P21(RAS); PROTO-ONCOGENE PROTEIN PP60(C-SRC); RAP GTP-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026659959     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.12.6.2606     Document Type: Article

References (48)

1. Buss, J. E., L. A. Quilliam, K. Kato, P. J. Casey, P. A. Solski, G. Wong, R. Clark, F. McCormick, G. M. Bokoch, and C. J. Der. 1991. The COOH-terminal domain of the RaplA (Krev-1) protein is isoprenylated and supports transformation by an H-Ras: RaplA chimeric protein. Mol. Cell. Biol. 11:1523-1530.
2. Buss, J. E., P. A. Solski, J. P. Schaeffer, M. J. MacDonald, and C. J. Der. 1989. Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal. Science 243:1600-1603.
3. Casey, P. J., P. A. Solski, C. J. Der, and J. E. Buss. 1989. p21ras is modified by the isoprenoid farnesol. Proc. Natl. Acad. Sci. USA 86:8323-8327.
4. Casey, P. J., J. A. Thissen, and J. F. Moomaw. 1991. Enzymatic modification of proteins with a geranylgeranyl isoprenoid. Proc. Natl. Acad. Sci. USA 88:8631-8635.
5. Cox, A. D., and C. J. Der. The ras/cholesterol connection: implications for ras oncogenicity. Crit. Rev. Oncogenesis, in press.
6. Der, C. J., and A. D. Cox. 1991. Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity. Cancer Cells 3:331-340.
7. H mutants deficient in GTP binding. Mol. Cell. Biol. 6:3291-3294.
8. Epstein, W. W., D. C. Lever, and H. C. Rilling. 1990. Prenylated proteins: synthesis of geranylgeranylcysteine and identification of this thioether amino acid as a component of proteins in CHO cells. Proc. Natl. Acad. Sci. USA 87:7352-7354.
9. Farnsworth, C. C., M. H. Gelb, and J. A. Glomset. 1990. Identification of geranylgeranyl-modified proteins in HeLa cells. Science 247:320-322.
10. Farnsworth, C. C., M. Kawata, Y. Yoshida, Y. Takai, M. H. Gelb, and J. A. Glomset. 1991. C terminus of the small GTP-binding protein smg p25A contains two geranylgeranylated cysteine residues and a methyl ester. Proc. Natl. Acad. Sci. USA 88:6196-6200.
11. Farnsworth, C. C., S. L. Wolda, M. H. Gelb, and J. A. Glomset. 1989. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem. 264:20422-20429.
12. Feig, L. A., and G. M. Cooper. 1988. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol. 8:3235-3243.
13. Finegold, A. A., D. I. Johnson, C. C. Farnsworth, M. H. Gelb, S. R. Judd, J. A. Glomset, and F. Tamanoi. 1991. Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for cys-xaa-xaa-leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product. Proc. Natl. Acad. Sci. USA 88:4448-4452.
14. Fujino, M., C. Kitada, Y. Sakagami, A. Isogai, S. Tamura, and A. Suzuki. 1980. Biological activity of synthetic analogs of tremerogen A-10. Naturwissenschaften 67:406-408.
15. Gibbs, J. B., M. D. Schaber, T. L. Schofield, E. M. Scolnick, and I. S. Sigal. 1989. Xenopus oocyte germinal-vesicle breakdown induced by [Va112]Ras is inhibited by a cytosol-localized Ras mutant. Proc. Natl. Acad. Sci. USA 86:6630-6634.
16. Glomset, J. A., M. H. Gelb, and C. C. Farnsworth. 1990. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem. Sci. 15:139-142.
17. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature (London) 343:425-430.
18. Gutierrez, L., A. I. Magee, C. J. Marshall, and J. F. Hancock. 1989. Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J. 8:1093-1098.
19. Hancock, J. F., K. Cadwallader, H. Paterson, and C. J. Marshall. 1991. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J. 10:4033-4039.
20. Haubruck, H., and F. McCormick. 1991. Ras p21: effectors and regulation. Biochim. Biophys. Acta 1072:215-229.
21. Khosravi-Far, R., R. J. Lutz, A. D. Cox, L. Conroy, J. R. Bourne, M. Sinensky, W. E. Balch, J. E. Buss, and C. J. Der. 1991. Isoprenoid modification of rab proteins terminating in CC/CXC motifs. Proc. Natl. Acad. Sci. USA 88:6264-6268.
22. Kinsella, B. T., and W. A. Maltese. 1991. rab GTP-binding proteins implicated in vesicular transport are isoprenylated in vitro at cysteines within a novel carboxyl-terminal motif. J. Biol. Chem. 266:8540-8544.
23. Kitayama, H., T. Matsuzaki, Y. Ikawa, and M. Noda. 1990. Genetic analysis of the Krev-1 gene: potentiation of its tumor suppressor activity by specific point mutations. Proc. Natl. Acad. Sci. USA 87:4284-4288.
24. Kitayama, H., Y. Sugimoto, T. Matsuzaki, Y. Ikawa, and M. Noda. 1989. A ras-related gene with transformation suppressor activity. Cell 56:77-84.
25. Lacal, P. M., C. Y. Pennington, and J. C. Lacal. 1988. Transforming activity of ras proteins translocated to the plasma membrane by a myristoylation sequence from the src gene product. Oncogene 2:533-538.
26. Lai, R. K., D. Perez-Sala, F. J. Canada, and R. R. Rando. 1990. The γ-subunit of transducin is farnesylated. Proc. Natl. Acad. Sci. USA 87:7673-7677.
27. Maltese, W. A. 1990. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4:3319-3328.
28. Marcus, S., G. A. Caldwell, D. Miller, C.-B. Xue, F. Naider, and J. M. Becker. 1991. Significance of C-terminal cysteine modifications to the biological activity of the Saccharomyces cerevisiae a-factor mating pheromone. Mol. Cell. Biol. 11:3603-3612.
29. Marshall, M. S., L. J. Davis, R. D. Keys, S. D. Mosser, W. S. Hill, E. M. Scolnick, and J. B. Gibbs. 1991. Identification of amino acid residues required for Ras p21 target activation. Mol. Cell. Biol. 11:3997-4004.
30. Maruta, H., J. Holden, A. Sizeland, and G. D'Abaco. 1991. The residues of ras and rap proteins that determine their GAP specificities. J. Biol. Chem. 266:11661-11668.
31. Michaeli, T., J. Field, R. Ballester, K. O'Neill, and M. Wigler. 1989. Mutants of H-ras that interfere with RAS effector function in Saccharomyces cerevisiae. EMBO J. 8:3039-3044.
32. Mulcahy, L. S., M. R. Smith, and D. W. Stacey. 1985. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (London) 313:241-243.
33. Patel, G., M. J. MacDonald, R. Khosravi-Far, M. Hisaka, and C. J. Der. 1992. Alternate mechanisms of ras activation are complementary and favor the formation of GTP-ras. Oncogene 7:283-288.
34. Plutner, H., A. D. Cox, S. Find, R. Khosravi-Far, J. R. Bourne, R. Schwaninger, C. J. Der, and W. E. Balch. 1991. Rab1b regulates vesicular transport between the ER and successive Golgi compartments. J. Cell. Biol. 115:31-43.
35. Powers, S., K. O'Neill, and M. Wigler. 1989. Dominant yeast and mammalian RAS mutants that interfere with the CDC25-dependent activation of wild-type RAS in Saccharomyces cerevisiae. Mol. Cell. Biol. 9:390-395.
36. Quilliam, L. A., C. J. Der, R. Clark, E. C. O'Rourke, K. Zhang, F. McCormick, and G. M. Bokoch. 1990. Biochemical characterization of baculovirus-expressed rap1a/Krev-1 protein and its regulation by GTPase activating proteins. Mol. Cell. Biol. 10:2901-2908.
37. Quinn, M. T., C. A. Parkos, L. Walker, S. H. Orkin, M. C. Dinauer, and A. J. Jesaitis. 1989. Association of a Ras-related protein with cytochrome b of human neutrophils. Nature (London) 342:198-200.
38. Reiss, Y., J. L. Goldstein, M. C. Seabra, P. J. Casey, and M. S. Brown. 1990. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62:81-88.
39. Ricketts, M. H., and A. D. Levinson. 1988. High-level expression of c-H-ras1 fails to fully transform Rat-1 cells. Mol. Cell. Biol. 8:1460-1468.
40. Rine, J., and S.-H. Kim. 1990. A role for isoprenoid lipids in the localization and function of an oncoprotein. The New Biologist 2:219-226.
41. Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467.
42. Seabra, M. C., Y. Reiss, P. J. Casey, M. S. Brown, and J. L. Goldstein. 1991. Protein farnesyltransferase and geranylgeranyl-transferase share a common α subunit. Cell 65:429-434.
43. Shalloway, D., A. D. Zelenetz, and G. M. Cooper. 1981. Molecular cloning and characterization of the chicken gene homologous to the transforming gene of Rous sarcoma virus. Cell 24:531-541.
44. Sigal, I. S., J. B. Gibbs, J. S. D'Alonzo, G. L. Temeles, B. S. Wolanski, S. H. Socher, and E. M. Scolnick. 1986. Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects. Proc. Natl. Acad. Sci. USA 83:952-956.
45. Smith, M. R., S. J. DeGudicibus, and D. W. Stacey. 1986. Requirement for c-ras proteins during viral oncogene transformation. Nature (London) 320:540-543.
46. Stacey, D. W., L. A. Feig, and J. B. Gibbs. 1991. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol. Cell. Biol. 11:4053-4064.
47. Stanton, V. P., D. W. Nichols, A. P. Laudano, and G. M. Cooper. 1989. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol. Cell. Biol. 9:639-647.
48. Zhang, K., M. Noda, W. C. Vass, A. G. Papageorge, and D. R. Lowy. 1990. Identification of small clusters of divergent amino acids that mediate the opposing effects of ras and Krev-1. Science 249:162-165.